Albert Labs International (FRA:VB50) EBITDA Margin %: 0.00% (As of Sep. 2023)


What is Albert Labs International EBITDA Margin %?

Albert Labs International FRA:VB50 EBITDA Margin % is 0.00% as of Sep. 2023.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Albert Labs International's EBITDA for the three months ended in Sep. 2023 was €-0.01 Mil. Albert Labs International's Revenue for the three months ended in Sep. 2023 was €0.00 Mil. Therefore, Albert Labs International's EBITDA margin for the quarter that ended in Sep. 2023 was 0.00%.

Albert Labs International  (FRA:VB50) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Albert Labs International EBITDA Margin % Related Terms

Albert Labs International EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Albert Labs International's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Albert Labs International EBITDA Margin % Chart

Albert Labs International Annual Data
Trend Dec21 Dec22
EBITDA Margin %
0.00 0.00

Albert Labs International Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:VB50 vs VRTX, REGN, SGEN: EBITDA Margin % Comparison

For the Biotechnology subindustry, Albert Labs International's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Albert Labs International EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Albert Labs International's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Albert Labs International's EBITDA Margin % falls into.


Albert Labs International EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Albert Labs International's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-2.875/0
= %

Albert Labs International's EBITDA Margin % for the quarter that ended in Sep. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2023 )/Revenue (Q: Sep. 2023 )
=-0.007/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Albert Labs International (FRA:VB50) has a EBITDA Margin % of 0.00% as of Sep. 2023. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Albert Labs International and its competitors.
Is Albert Labs International's EBITDA Margin % too high?
Albert Labs International's current EBITDA Margin % is 0.00%.
How does Albert Labs International's EBITDA Margin % compare to VRTX and REGN?
Albert Labs International's EBITDA Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Albert Labs International and its competitors. Albert Labs International's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Albert Labs International stock overvalued right now?
Albert Labs International (FRA:VB50) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Albert Labs International (FRA:VB50), the current EBITDA Margin % is 0.00% as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Albert Labs International Business Description

Address 201-6996 Merritt Avenue, Burnaby, BC, CAN, V5J 4R6
Albert Labs International Corp is a laboratory-based, clinical research, and drug development enterprise addressing mental health care needs. The company is focusing on Real World Evidence (RWE) the company will initially look to commercialize its mycelium-based KRN-101 medicine and treatment with the help of a clinical pathway.